Loading…
Operates in Pharma — Distribution. Per the activity note to the FY2023 annual report, the company carries out wholesale trade in pharmaceutical goods.
| Ratio | 2021 | 2022 | 2023 |
|---|---|---|---|
| Margins | |||
| Gross Margin | 22.4% | 23.1% | 23.0% |
| EBITDA Margin | 19.4% | 15.7% | -71.5% |
| EBITDAR | 588 | 363 | -138 |
| EBITDAR Margin | 19.4% | 15.7% | -71.5% |
| EBIT Margin | 19.4% | 15.7% | -71.5% |
| Net Profit Margin | 19.1% | 15.4% | -73.1% |
| Operating Expense % of Sales | 3.0% | 7.3% | 94.5% |
| Returns | |||
| Return on Assets (ROA) | 51.0% | 23.5% | -15.4% |
| Return on Equity (ROE) | 67.2% | 33.6% | -15.5% |
| ROIC [EBIT / Invested Capital] | 62.6% | 35.4% | -15.2% |
| Leverage & debt balances | |||
| Debt-to-Assets | 7.4% | 3.0% | 0.1% |
| Debt-to-Equity | 0.10x | 0.04x | 0.00x |
| Debt-to-EBITDA | 0.14x | 0.12x | N/A |
| Equity-to-Assets | 75.8% | 69.9% | 99.3% |
| Net Debt | 76 | -30 | -0 |
| Cash & Equivalents | 8 | 75 | 1 |
| Total Debt | 84 | 45 | 1 |
| Liquidity & working capital | |||
| Current Ratio | 5.95x | 3.69x | N/A |
| Quick Ratio | 5.95x | 3.69x | N/A |
| Cash Ratio | 0.04x | 0.18x | N/A |
| Total Current Assets | 1,131 | 1,508 | 918 |
| Total Current Liabilities | 190 | 409 | N/A |
| Inventory | N/A | N/A | N/A |
| Trade Receivables | 196 | 865 | 369 |
| Trade Payables | 188 | 409 | N/A |
| Net Working Capital | 941 | 1,098 | 918 |
| Net Working Capital % of Revenue | 31.1% | 47.7% | 475.1% |
| Trade Working Capital | 8 | 456 | 369 |
| Trade Working Capital % of Revenue | 0.3% | 19.8% | 190.7% |
| Change in Trade Working Capital | N/A | 449 | -88 |
| Turnover & efficiency | |||
| Inventory Turnover | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | N/A | N/A | N/A |
| Receivables Turnover | 15.47x | 2.66x | 0.52x |
| Days Sales Outstanding (DSO) | 23.6 | 137.1 | 696.1 |
| Payables Turnover | 12.49x | 4.33x | N/A |
| Days Payable Outstanding (DPO) | 29.2 | 84.2 | N/A |
| Cash Conversion Cycle | -5.6 days | 52.8 days | 696.1 days |
| Asset Turnover | 2.67x | 1.53x | 0.21x |
| Cash flow & dividends | |||
| Operating Cash Flow | N/A | N/A | N/A |
| Free Cash Flow (OCF − Capex proxy) | N/A | N/A | N/A |
| Cash Conversion (OCF / EBITDA) | N/A | N/A | N/A |
| Dividends Declared | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in GEL, thousands. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set.